CL2023002871A1 - Composiciones nasales que comprenden alcaftadina - Google Patents

Composiciones nasales que comprenden alcaftadina

Info

Publication number
CL2023002871A1
CL2023002871A1 CL2023002871A CL2023002871A CL2023002871A1 CL 2023002871 A1 CL2023002871 A1 CL 2023002871A1 CL 2023002871 A CL2023002871 A CL 2023002871A CL 2023002871 A CL2023002871 A CL 2023002871A CL 2023002871 A1 CL2023002871 A1 CL 2023002871A1
Authority
CL
Chile
Prior art keywords
alcaftadine
nasal
nasal compositions
methods
pharmaceutically acceptable
Prior art date
Application number
CL2023002871A
Other languages
English (en)
Spanish (es)
Inventor
Akhilesh Sharma
Babasaheb Aware
Viraj Shah
Amol Aiwale
Original Assignee
Alkem Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkem Laboratories Ltd filed Critical Alkem Laboratories Ltd
Publication of CL2023002871A1 publication Critical patent/CL2023002871A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CL2023002871A 2021-04-01 2023-09-26 Composiciones nasales que comprenden alcaftadina CL2023002871A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN202121015680 2021-04-01

Publications (1)

Publication Number Publication Date
CL2023002871A1 true CL2023002871A1 (es) 2024-01-26

Family

ID=76523258

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023002871A CL2023002871A1 (es) 2021-04-01 2023-09-26 Composiciones nasales que comprenden alcaftadina

Country Status (12)

Country Link
US (6) US20240173331A1 (OSRAM)
EP (1) EP4312973A1 (OSRAM)
JP (1) JP2024512121A (OSRAM)
KR (1) KR20230163413A (OSRAM)
CN (1) CN117120029A (OSRAM)
AU (1) AU2021437358A1 (OSRAM)
BR (1) BR112023019795A2 (OSRAM)
CA (1) CA3213156A1 (OSRAM)
CL (1) CL2023002871A1 (OSRAM)
MX (1) MX2023011546A (OSRAM)
WO (1) WO2022208146A1 (OSRAM)
ZA (1) ZA202308388B (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240173331A1 (en) * 2021-04-01 2024-05-30 Alkem Laboratories Limited Nasal compositions comprising alcaftadine
CN114504037B (zh) * 2022-01-14 2024-12-03 云南中茶茶业有限公司 一种茶叶发酵瓶用出瓶机
US11992493B1 (en) * 2022-10-25 2024-05-28 Liangdan Sun Use of compound or pharmaceutical derivative thereof in inhibiting CaMK2G protein activity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2053678T3 (es) 1987-11-13 1994-08-01 Asta Medica Ag Procedimiento para preparar un medicamento con contenido de azelastina para la aplicacion nasal y/u ocular.
IL101850A (en) 1991-06-13 1996-01-31 Janssen Pharmaceutica Nv 11-(4-Piperidinyl)-imidazo (2,1-b) (3) benzazepine derivatives their preparation and pharmaceutical compositions containing them
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
BRPI0615032A2 (pt) 2005-09-01 2011-04-26 Biolipox Ab composição farmacêutica, processo para a preparação da mesma, e, uso de uma composição
JP5292277B2 (ja) 2006-03-31 2013-09-18 ビスタコン・フアーマシユーチカルズ・エルエルシー 眼アレルギーの処置
JP2014518278A (ja) * 2011-06-29 2014-07-28 アラーガン インコーポレイテッド 蕁麻疹の治療に用いるアルカフタジン
CN102283849A (zh) 2011-06-29 2011-12-21 北京阜康仁生物制药科技有限公司 一种含有阿卡他定的药物组合物
JP7191022B2 (ja) 2017-07-28 2022-12-16 参天製薬株式会社 アルカフタジン又はその塩を含有する水性医薬組成物
JP7791119B2 (ja) * 2020-06-15 2025-12-23 アルケム・ラボラトリーズ・リミテッド アルカフタジンとコルチコステロイドの組み合わせ
US20240173331A1 (en) * 2021-04-01 2024-05-30 Alkem Laboratories Limited Nasal compositions comprising alcaftadine

Also Published As

Publication number Publication date
US20240173331A1 (en) 2024-05-30
WO2022208146A1 (en) 2022-10-06
CA3213156A1 (en) 2022-10-06
JP2024512121A (ja) 2024-03-18
US12274702B2 (en) 2025-04-15
ZA202308388B (en) 2025-11-26
US20250064826A1 (en) 2025-02-27
CN117120029A (zh) 2023-11-24
US20250064827A1 (en) 2025-02-27
US20250064828A1 (en) 2025-02-27
AU2021437358A1 (en) 2023-09-14
EP4312973A1 (en) 2024-02-07
BR112023019795A2 (pt) 2023-11-07
US20250064825A1 (en) 2025-02-27
KR20230163413A (ko) 2023-11-30
US20260007682A1 (en) 2026-01-08
MX2023011546A (es) 2023-10-06

Similar Documents

Publication Publication Date Title
JOP20210109A1 (ar) مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CO2020004301A2 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih
DOP2019000201A (es) Compuestos inhibidores del vih
MX2021005898A (es) Terapia de combinacion que incluye un inhibidor de krasg12c y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
MX2017015521A (es) Derivados de heterociclilos sustituidos como inhibidores de cdk.
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
MX2022015965A (es) Combinacion de alcaftadina y un corticoesteroide.
CO2017004649A2 (es) Esteroides neuroactivos para trastornos del snc
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
MX2023011546A (es) Composiciones nasales que comprenden alcaftadina.
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
JOP20180025A1 (ar) مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MX2018003256A (es) Derivados de indol mono- o disustituidos como inhibidores de la replicacion viral del dengue.
CR20180496A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
EA201790700A1 (ru) Моно- или дизамещенные индолы в качестве ингибиторов репликации вирусов денге
MX2017009309A (es) Derivados de indol mono o disustituido como inhibidores de la replicacion del virus del dengue.
DOP2013000314A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
CO2017005806A2 (es) Nuevos derivados de bencimidazol como agentes antihistamínicos
EA201692278A1 (ru) Комбинации формотерола и будесонида для лечения хобл
CR20150327A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
MX2018012439A (es) Composiciones y metodos para el tratamiento de enfermedades de la mucosa nasal y paranasal con agonistas del receptor de acetilcolina de tipo nicotinico.
BR112022007623A2 (pt) Composições para prevenir ou tratar doenças pulmonares obstrutivas crônicas (dpoc)
EA202092278A1 (ru) Римегепант для связанных с cgrp расстройств